Assessment of the Increased Risk of Infection Following an Ultratrail
NCT ID: NCT06089174
Last Updated: 2023-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1300 participants
INTERVENTIONAL
2023-10-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The invetigators' hypothesis is therefore that ultratrailers are overexposed to the risk of infection due to immunodepression resulting from practising this sport. In order to support this hypothesis, the investigators would like to look at infectious complications in general and ear-nose and throat episodes (rhinitis, pharyngitis, laryngitis, etc.) in particular, which are the most common infections encountered in primary care, along with urinary tract infections.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Inflammation During a 100 Miles
NCT03256006
Problems Associated With Ultramarathon
NCT01602146
Microbiota is Related With Increasing Infection Rates After Splenectomy
NCT03420599
Evaluation of Biological Markers of Mesenteric Ischemia During an Ultra-trail
NCT03205098
Promoting Immune Health by Intermittent Fasting: a Pilot Study
NCT05898360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposed (Runners)
Ultra-endurance runners taking part in an ultra-trail of 72 km, 109 km or 165 km
Ultra-trail
Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
Non-exposed (companions)
Runners' companions not running
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultra-trail
Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participating in a Grand Raid de la Réunion 2023 race (Mascareignes, Trail de Bourbon, Diagonale des Fous)
* Have a companion living under the same roof during the week preceding the race and the 21 days following the race and who agrees to answer the questionnaires
* Do not object to the research
Exclusion Criteria
* A protected adult (guardianship or curatorship) or under court protection
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jean Monnet University
OTHER
Hôpital Privé de la Loire- Saint Etienne
UNKNOWN
Centre Hospitalier Universitaire de la Réunion
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas BOUSCAREN, MD
Role: PRINCIPAL_INVESTIGATOR
CHU de la Réunion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Réunion
Saint-Denis, , Reunion
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023/CHU/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.